RPR riluzole 100 mg shows 56.8% survival at 18 months v. 50.4% in placebo -- Phase III ALS data.

RPR RILUZOLE 100 MG SURVIVAL AT 18 MONTHS IS 56.8% OF ALS PATIENTS compared to 50.4% on placebo, Vincent Meininger, Hopital de la Pitie-Salpetriere, Paris, reported May 10 during the American Academy of Neurology meeting in Seattle. After 18 months of treatment, 134 of 236 patients treated with Rilutek (riluzole) 100 mg for amyotrophic lateral sclerosis were still alive, compared to 122 of 242 placebo patients. Patients treated with 50 mg had a 55% survival rate and patients treated with 200 mg had a 57% rate.